Scrip 100: Has novelty in the depression pipeline hit a wall?
This article was originally published in Scrip
Executive Summary
The health of the depression pipeline was brought into question in early 2014 when Shire's Vyvanse (lisdexamfetamine dimesylate) failed in Phase III, becoming just another product to fall at the final development hurdles for major depressive disorder (MDD).
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.